Nucleome Therapeutics is a gene therapy technology developer whose cell-type-specific platform creates high-resolution 3D genome structure maps and enables proportional verification of different functions in primary cell types, resulting in the discovery and development of new, Better and Safer Medicines. Nucleome Therapeutics announced the closing of an oversubscribed £37.5 million ($42.4 million) Series A round. The round was led by M Ventures, with participation from JJDC, Pfizer Pfizer, UK Patient Capital and founding investor Oxford Scientific.
This article is reproduced from: https://www.itjuzi.com/investevent/13624949
This site is for inclusion only, and the copyright belongs to the original author.